Literature DB >> 31919062

Paediatric porphyria and human hemin: a treatment challenge in a lower middle income country.

Syeda Anum Fatima1, Humaira Jurair2, Qalab Abbas2, Arshalooz Jamila Rehman2.   

Abstract

Here, we report a case of a 15-year-old girl who presented to the emergency department with symptoms of abdominal pain, nausea, vomiting and seizures. She was diagnosed with acute intermittent porphyria. Treatment was started by removing all porphogenic drugs, providing high glucose intake (oral and intravenous), which initially resulted in good clinical outcomes. However, she deteriorated again and also developed neurological manifestation (paraplegia) for which she required mechanical ventilation because of acute respiratory failure. This time she was initiated on human hemin for four consecutive days. After 2 days of therapy, her porphobilinogen levels decreased to 50% of the initial raised value. Increased lactic acid and blood urea nitrogen were the two side effects observed after the treatment, with no apparent signs of acute kidney injury. To the best of our knowledge, in paediatric population, this is the first reported case of treatment of acute intermittent porphyria with human hemin in Pakistan. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  nutritional support; paediatrics (drugs and medicines); pharmacology and therapeutics

Mesh:

Substances:

Year:  2020        PMID: 31919062      PMCID: PMC6954746          DOI: 10.1136/bcr-2019-232236

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  25 in total

Review 1.  Treatment of acute porphyria.

Authors:  G H Elder; R J Hift
Journal:  Hosp Med       Date:  2001-07

Review 2.  Guide to porphyrias. A historical and clinical perspective.

Authors:  Stacy E Foran; György Abel
Journal:  Am J Clin Pathol       Date:  2003-06       Impact factor: 2.493

Review 3.  Porphyric neuropathy.

Authors:  James W Albers; John K Fink
Journal:  Muscle Nerve       Date:  2004-10       Impact factor: 3.217

4.  Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure.

Authors:  Shirin Attarian; Chunli Yu; Karl E Anderson; Ellen W Friedman
Journal:  Blood Adv       Date:  2017-06-05

5.  Screening for latent acute intermittent porphyria: the value of measuring both leucocyte delta-aminolaevulinic acid synthase and erythrocyte uroporphyrinogen-1-synthase activities.

Authors:  K E McColl; M R Moore; G G Thompson; A Goldberg
Journal:  J Med Genet       Date:  1982-08       Impact factor: 6.318

Review 6.  A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady'.

Authors:  Richard J Hift; Timothy J Peters; Peter N Meissner
Journal:  J Clin Pathol       Date:  2011-11-02       Impact factor: 3.411

Review 7.  Variegate porphyria.

Authors:  R E Kirsch; P N Meissner; R J Hift
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

8.  Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases.

Authors:  R Kauppinen; P Mustajoki
Journal:  Medicine (Baltimore)       Date:  1992-01       Impact factor: 1.889

9.  Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature.

Authors:  P W Kaplan; D V Lewis
Journal:  J Child Neurol       Date:  1986-01       Impact factor: 1.987

10.  Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries.

Authors:  Murugesan R Prabahar; Rajendran Manorajan; Devasahayam Sathiyakumar; Periyasamy Soundararajan; Matcha Jayakumar
Journal:  Hemodial Int       Date:  2008-01       Impact factor: 1.812

View more
  1 in total

Review 1.  Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.

Authors:  Matteo Marcacci; Andrea Ricci; Chiara Cuoghi; Stefano Marchini; Antonello Pietrangelo; Paolo Ventura
Journal:  Orphanet J Rare Dis       Date:  2022-04-07       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.